Caladrius Biosciences, Inc. – NASDAQ:CLBS
Caladrius Biosciences stock price today
Caladrius Biosciences stock price monthly change
Caladrius Biosciences stock price quarterly change
Caladrius Biosciences stock price yearly change
Caladrius Biosciences key metrics
Market Cap | 3.35M |
Enterprise value | N/A |
P/E | -1.08 |
EV/Sales | N/A |
EV/EBITDA | 0.25 |
Price/Sales | N/A |
Price/Book | 0.31 |
PEG ratio | N/A |
EPS | -0.40 |
Revenue | N/A |
EBITDA | -27.01M |
Income | -24.57M |
Revenue Q/Q | N/A |
Revenue Y/Y | 397.86% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCaladrius Biosciences stock price history
Caladrius Biosciences stock forecast
Caladrius Biosciences financial statements
| Sep 2021 | 0 | -6.92M | |
|---|---|---|---|
| Dec 2021 | 125.58M | -6.79M | -5.41% |
| Mar 2022 | 0 | -4.22M | |
| Jun 2022 | 0 | -6.62M |
| 2022-03-22 | -0.14 | -0.11 |
|---|---|---|
| 2022-05-05 | -0.1 | -0.07 |
| 2022-08-04 | -0.1 | -0.11 |
| Sep 2021 | 102538000 | 4.12M | 4.02% |
|---|---|---|---|
| Dec 2021 | 97008000 | 5.00M | 5.16% |
| Mar 2022 | 91463000 | 3.22M | 3.52% |
| Jun 2022 | 85877000 | 3.74M | 4.36% |
| Sep 2021 | -5.03M | 4.94M | -64K |
|---|---|---|---|
| Dec 2021 | -4.60M | 16.45M | 21K |
| Mar 2022 | -5.64M | -6.09M | -168K |
| Jun 2022 | -5.06M | 25.63M | 29K |
Caladrius Biosciences alternative data
| Aug 2023 | 27 |
|---|---|
| Sep 2023 | 27 |
| Oct 2023 | 27 |
| Nov 2023 | 27 |
| Dec 2023 | 27 |
| Jan 2024 | 27 |
| Feb 2024 | 27 |
| Apr 2024 | 27 |
| May 2024 | 27 |
| Jun 2024 | 27 |
| Jul 2024 | 27 |
Caladrius Biosciences other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2021 | 33785 | 0 |
| Quarter | Transcript |
|---|---|
| Q2 2022 4 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 5 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 22 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 4 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. (1957) Pres, Chief Executive Officer & Director | $972,930 |
Mr. Todd C. Girolamo M.B.A., J.D., Esq. (1966) Chief Legal Officer, Senior Vice President of Corporation Devel. & Corporation Sec. | $456,390 |
Dr. William K. Sietsema Ph.D. (1956) Vice President of Global Regulatory Affairs | $350,550 |
-
What's the price of Caladrius Biosciences stock today?
One share of Caladrius Biosciences stock can currently be purchased for approximately $0.43.
-
When is Caladrius Biosciences's next earnings date?
Unfortunately, Caladrius Biosciences's (CLBS) next earnings date is currently unknown.
-
Does Caladrius Biosciences pay dividends?
No, Caladrius Biosciences does not pay dividends.
-
How much money does Caladrius Biosciences make?
Caladrius Biosciences has a market capitalization of 3.35M. Caladrius Biosciences made a loss 27.47M US dollars in net income (profit) last year or -$0.11 on an earnings per share basis.
-
What is Caladrius Biosciences's stock symbol?
Caladrius Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "CLBS".
-
What is Caladrius Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Caladrius Biosciences?
Shares of Caladrius Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Caladrius Biosciences's key executives?
Caladrius Biosciences's management team includes the following people:
- Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. Pres, Chief Executive Officer & Director(age: 68, pay: $972,930)
- Mr. Todd C. Girolamo M.B.A., J.D., Esq. Chief Legal Officer, Senior Vice President of Corporation Devel. & Corporation Sec.(age: 59, pay: $456,390)
- Dr. William K. Sietsema Ph.D. Vice President of Global Regulatory Affairs(age: 69, pay: $350,550)
-
How many employees does Caladrius Biosciences have?
As Jul 2024, Caladrius Biosciences employs 27 workers.
-
When Caladrius Biosciences went public?
Caladrius Biosciences, Inc. is publicly traded company for more then 29 years since IPO on 3 Nov 1995.
-
What is Caladrius Biosciences's official website?
The official website for Caladrius Biosciences is caladrius.com.
-
Where are Caladrius Biosciences's headquarters?
Caladrius Biosciences is headquartered at 110 Allen Rd, Basking Ridge, NEW JERSEY.
-
How can i contact Caladrius Biosciences?
Caladrius Biosciences's mailing address is 110 Allen Rd, Basking Ridge, NEW JERSEY and company can be reached via phone at +1 908 842 0100.
Caladrius Biosciences company profile:
Caladrius Biosciences, Inc.
caladrius.comNASDAQ
27
Biotechnology
Healthcare
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Basking Ridge, NEW JERSEY 07920
CIK: 0000320017
ISIN: US1280582032
CUSIP: 128058203
